These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

814 related articles for article (PubMed ID: 17164953)

  • 1. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
    Huang SS; Lee MH; Leu HS
    J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
    Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
    J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia.
    Martínez JA; Aguilar J; Almela M; Marco F; Soriano A; López F; Balasso V; Pozo L; Mensa J
    J Antimicrob Chemother; 2006 Nov; 58(5):1082-5. PubMed ID: 16950822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the clinical significance of production of extended-spectrum beta-lactamases (ESBL) by Enterobacteriaceae.
    Henshke-Bar-Meir R; Yinnon AM; Rudensky B; Attias D; Schlesinger Y; Raveh D
    Infection; 2006 Apr; 34(2):66-74. PubMed ID: 16703295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
    Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children.
    Zaoutis TE; Goyal M; Chu JH; Coffin SE; Bell LM; Nachamkin I; McGowan KL; Bilker WB; Lautenbach E
    Pediatrics; 2005 Apr; 115(4):942-9. PubMed ID: 15805368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features of nosocomial infections by extended-spectrum beta-lactamase-producing Enterobacteriaceae in neonatal intensive care units.
    Chiu S; Huang YC; Lien RI; Chou YH; Lin TY
    Acta Paediatr; 2005 Nov; 94(11):1644-9. PubMed ID: 16303704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the United Arab Emirates.
    Al-Zarouni M; Senok A; Rashid F; Al-Jesmi SM; Panigrahi D
    Med Princ Pract; 2008; 17(1):32-6. PubMed ID: 18059098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli.
    Bin C; Hui W; Renyuan Z; Yongzhong N; Xiuli X; Yingchun X; Yuanjue Z; Minjun C
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):351-7. PubMed ID: 16934430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates.
    Lee CH; Su LH; Tang YF; Liu JW
    J Antimicrob Chemother; 2006 Nov; 58(5):1074-7. PubMed ID: 16971415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program.
    Bhavnani SM; Ambrose PG; Craig WA; Dudley MN; Jones RN;
    Diagn Microbiol Infect Dis; 2006 Mar; 54(3):231-6. PubMed ID: 16423491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp.: a nested case-control study from a tertiary hospital in London.
    Skippen I; Shemko M; Turton J; Kaufmann ME; Palmer C; Shetty N
    J Hosp Infect; 2006 Oct; 64(2):115-23. PubMed ID: 16859810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
    Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome.
    Du B; Long Y; Liu H; Chen D; Liu D; Xu Y; Xie X
    Intensive Care Med; 2002 Dec; 28(12):1718-23. PubMed ID: 12447513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-spectrum beta-lactamase-producing Enterobacteriaceae at Middlemore Hospital.
    Briggs S; Ussher J; Taylor S
    N Z Med J; 2005 Jul; 118(1218):U1563. PubMed ID: 16027752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
    Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
    Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
    Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
    Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bacteremia. Risk factors and outcome in the eastern region of Saudi Arabia.
    Memon JI; Rehmani RS; Ahmed MU; Elgendy AM; Nizami IY
    Saudi Med J; 2009 Jun; 30(6):803-8. PubMed ID: 19526164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Risk factors and prognosis in 31 patients with extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bloodstream infection].
    Chen YH; Yao WZ; Wu R; Zhou QT; Liu ZY; Zhang XW
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Nov; 31(11):815-9. PubMed ID: 19080534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.